December 04, 2022

Brent Willis of Voyageur Pharmaceuticals discusses the high IRR and NPV in its recent PEA

In a recent InvestorIntel interview, Tracy Weslosky spoke with Brent Willis, President and CEO of Voyageur Pharmaceuticals Ltd. (TSXV: VM) about Voyageur’s recent Preliminary Economic Assessment resulting in an internal rate of return (IRR) of 137% and a NPV of $344 million for their Frances Creek Pharmaceutical Barium Project located in British Columbia, Canada.

In this InvestorIntel interview, which may also be viewed on YouTube (click here to subscribe to the InvestorIntel Channel), Brent Willis highlighted the limited supply of naturally occurring, high grade, barium sulfate. He went on to explain how having one of the most accessible and highest-grade barium sulfate deposits in the world, grading over 98% barium sulfate, allows Voyageur to become a low-cost producer of high-value barium sulfate products and ensure full integration of the radiology drug market. Brent also provided an update on Voyageur’s newly created Scientific Advisory Board of world-class leading physicians in the medical radiology industry.

To watch the full interview, click here.

About Voyageur Pharmaceuticals Ltd.

Voyageur is a Canadian public company listed on the TSXV under the trading symbol VM. Voyageur is focused on the development of barite and iodine Active Pharmaceutical Ingredients (“API”) and high-performance cost-effective imaging contrast agents for the medical radiology marketplace. Voyageur’s goal is to initially generate positive cash flow from operations using third party GMP pharmaceutical manufacturers in Canada and internationally. Ultimately, Voyageur has plans to build all the required infrastructure to become 100% self-sufficient with all manufacturing. Voyageur owns a 100% interest in three barium sulphate (barite) projects including the Frances Creek property, suitable in grade for the pharmaceutical barite marketplace, with interests in a high-grade iodine, lithium & bromine brine project located in Utah, USA.

Voyageur is moving forward with its business plan of becoming the only fully integrated company in the radiology medical field, by controlling all primary input costs under the motto of: “From the Earth to the Bottle”.

To learn more about Voyageur Pharmaceuticals Ltd., click here

Disclaimer: Voyageur Pharmaceuticals Ltd. is an advertorial member of InvestorIntel Corp.

This interview, which was produced by InvestorIntel Corp. (IIC) does not contain, nor does it purport to contain, a summary of all the material information concerning the “Company” being interviewed. IIC offers no representations or warranties that any of the information contained in this interview is accurate or complete.

This presentation may contain “forward-looking statements” within the meaning of applicable Canadian securities legislation. Forward-looking statements are based on the opinions and assumptions of the management of the Company as of the date made. They are inherently susceptible to uncertainty and other factors that could cause actual events/results to differ materially from these forward-looking statements. Additional risks and uncertainties, including those that the Company does not know about now or that it currently deems immaterial, may also adversely affect the Company’s business or any investment therein.

Any projections given are principally intended for use as objectives and are not intended, and should not be taken, as assurances that the projected results will be obtained by the Company. The assumptions used may not prove to be accurate and a potential decline in the Company’s financial condition or results of operations may negatively impact the value of its securities. Prospective investors are urged to review the Company’s profile on Sedar.com and to carry out independent investigations in order to determine their interest in investing in the Company.

If you have any questions surrounding the content of this interview, please contact us at +1 416 792 8228 and/or email us direct at info@investorintel.com.

Disclaimer: The author of this post may or may not be a shareholder of any of the companies mentioned in this column. None of the companies discussed in the above feature have paid for this content. The writer of this article/post/column/opinion is not an investment advisor, and is neither licensed to nor is making any buy or sell recommendations. For more information about this or any other company, please review their public documents to conduct your own due diligence. To access the InvestorIntel.com disclaimer and other important legal notices, click here.

3 responses

  1. Joerg Erassme Avatar
    Joerg Erassme

    In Voyageur Pharmaceutical’s press release from January 2022 they write
    “Current pricing of 97.5% BaSO4 available from China has a delivered price of $4,760 USD per tonne, or $5,960 CAD per tonne.” This pricing is used for bulk sales of BaSO4, that are not used in the manufacture of pharmaceutical products. Voyageur’s product has a higher quality of 98.3% BaSO4 and pricing in the PEA is based on 97.5% BaSO4 product.”
    Having been working in the Barium Sulfate business I do not see these high prices for Barium Sulfate (natural and chemical) nor the Chinese export statistics and neither in prices of European manufacturers. Average FOB price for Chinese exports for paint grade are about 650 US-$ per ton. The Barium Sulfate price that is mentioned here is paid for very special high-purity grades with low volumes for high-tec applications.

  2. Tracy Weslosky Avatar
    Tracy Weslosky

    Thank you for your feedback. We took your comment and sent it to Brent who responded immediately. Then, I requested whether or not I could reprint the reply and he agreed. Here you go —:

    REPLY:
    Hi Tracy,

    Those prices are what we are actually paying today for barite landed in Calgary. The Chinese informed us recently that natural 97.5% is no longer available and can only ship synthetic blanc fix. I am getting quotes from Germany as I am concerned about Chinese supply.

    From our testing with SGS we are achieving blanc fix grades of 99.8%, 100%, 99.0% & 97.8% BaSO4. We will be focused on the small markets and our pea is only based on 500 tonne a month of sales. Very small.

    We are not selling paint grade, we are looking at markets that consume 99% blanc fix.

    Thanks

    Brent Willis
    CEO
    Voyageur Pharmaceuticals Ltd”

  3. barrister Avatar
    barrister

    Veгy great post. I just stumbled upon your weblog and wanted to say that І havе really
    enjoyed surfіng aгound your weblog posts. In any case I’ll be subscriЬing for your rsѕ fеed and I hope
    yⲟu write ɑgain very so᧐n!

Leave a Reply

Your email address will not be published. Required fields are marked *